Sponsors (2)
Official title: Extend expiring health provisions and improve health care delivery.
Introduced March 6, 2025 by Ronald Lee Wyden · Last progress March 6, 2025
The bill expands funding, transparency, and public‑health preparedness which can improve access, lower hidden drug costs, and strengthen readiness — but it imposes substantial reporting, privacy, and implementation burdens and raises federal spending that may shift costs to taxpayers, plans, providers, or patients.
Medicare Part D and group health plan enrollees, employers, and insurers gain much greater drug‑pricing transparency because PBMs, plans, and sponsors must provide regular, machine‑readable, claim‑ and drug‑level reports, pass through rebates in certain contexts, and permit audits.
Low‑income, uninsured, and underserved patients get expanded access to primary care and targeted services because community health centers, the National Health Service Corps, teaching health center GME, and disease‑specific programs (diabetes, WTC program, dental, sickle cell, breast & cervical cancer screening) receive substantial, multi‑year funding authorizations and short‑term transitional aid
States, hospitals, and local public‑health agencies gain stronger preparedness and surveillance capacity because the bill expands Hospital Preparedness Program funding, creates/finances regional biocontainment labs, establishes wastewater surveillance grants, mandates an AMR strategy, strengthens stockpile management, and supports diagnostic testing preparedness.
Millions of patients, employers, plans, PBMs, pharmacies, and state agencies face substantial new compliance, reporting, audit, and IT requirements across drug pricing, PBM reporting, claims‑level disclosure, Medicaid reporting, and preparedness programs, creating major administrative burdens and implementation costs.
Taxpayers and federal budgets will face significantly higher authorizations and program spending (community health center funding, NHSC/GME, preparedness, biocontainment labs, overdose and behavioral‑health programs, and multiple disease‑program authorizations), increasing deficit or offset pressures.
Patients and communities face elevated privacy and data‑security risks because extensive claims‑level disclosures, surveillance reporting, and new wastewater monitoring authority increase the chance of re‑identification or sensitive data exposure if safeguards fail.
Based on analysis of 36 sections of legislative text.
Imposes PBM transparency and reporting across Part D and group plans, creates streamlined out‑of‑State Medicaid provider enrollment for children, adjusts hospital/Medicare payment timing, expands pediatric drug requirements, and funds public health programs and biocontainment labs.
Requires states and health plans to make it easier for eligible out‑of‑State providers to enroll in Medicaid for care of children, expands Medicaid reporting for home‑and‑community‑based services waitlists, tightens hospital and Medicare payment timing rules, and extends multiple public health program authorizations and funding lines. The bill also creates wide PBM and pharmacy‑data transparency and reporting mandates across Medicare Part D, group health plans, and federal law, updates pediatric drug study requirements, caps asserted patents in certain biosimilar suits, funds regional biocontainment labs, and makes other targeted public health and Controlled Substances Act changes. Many provisions take effect on different schedules (some after enactment, some 30 months later, some January 1, 2027–2028, and others with multi‑year funding windows). The package mixes program authorizations and appropriations, regulatory rulemaking directions, reporting and disclosure duties for PBMs and plans, payment‑policy adjustments for hospitals and Medicare, and public health workforce and infrastructure investments.